Characterization as Strategy: De-risking CMC with High-Resolution Analytics

A comprehensive analytical package is the core of any successful CMC program for advanced therapeutics and complex biologics. Applying proven intelligence in analytical development accelerates these programs toward IND submission. The data generated informs every strategic decision from process development to final formulation.

When analytical characterization is treated as a late-stage validation exercise, minor variabilities can go undetected. These issues often compound during process scale-up, leading to delays and costly rework. An incomplete understanding of product attributes like vector genome integrity or particle composition introduces significant risk into the manufacturing process and, potentially, the clinical outcome.

This principle of analytical fidelity has deep roots. Foundational work in vector discovery highlighted the necessity of using high-performance tools to ensure the accurate amplification and isolation of AAV genomes from source material (PMID: 34448594). An imprecise reading at the discovery stage corrupts the entire downstream development path. The same logic applies directly to CMC analytics: what you cannot measure with precision, you cannot control with confidence.

A modern, high-resolution analytical platform provides a multi-dimensional view of the product. This moves far beyond simple titer measurements and creates a detailed fingerprint of the therapeutic candidate.

• Particle Characterization: Differentiates full, empty, and partially-filled capsids, a key determinant of product potency and potential immunogenicity.
• Mass Spectrometry: Confirms the identity and purity of capsid proteins and can detect post-translational modifications.
• Cell-Based Potency Assays: Provides a functional measure of biological activity that is directly relevant to the intended clinical effect.

Building this comprehensive data package early in development creates a stable foundation for the entire program. It allows for the establishment of meaningful quality attributes that guide process optimization and demonstrate manufacturing consistency to regulators. This approach has been integral to the 100% successful IND rate achieved by our core scientific team for partner programs since 2019, a track record that now forms the foundation of Franklin Biolabs.

A phase-appropriate analytical strategy deploys the right high-resolution methods at the right time. This approach builds a data-driven narrative that anticipates and answers regulatory questions, transforming analytics from a quality control function into a strategic asset that de-risks the path to the clinic.